Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus PHENYLEPHRINE HYDROCHLORIDE IN 0 9 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus PHENYLEPHRINE HYDROCHLORIDE IN 0 9 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Phenylephrine is a selective α1-adrenergic receptor agonist causing vasoconstriction, increasing peripheral vascular resistance and blood pressure.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: initial rate 100-180 mcg/min, titrate to effect; maintenance 40-60 mcg/min. Concentrations: 100 mcg/mL (10 mg in 100 mL NS) or 200 mcg/mL (20 mg in 100 mL NS). Administer via central line preferred.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life: 2-3 hours; clinical context: requires repeated dosing or continuous infusion for sustained effect.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily renal (80-90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Category C
Category A/B
Electrolyte
Electrolyte